Abstract
Age-related neurodegenerative disease research needs aging models.
Highlights
We all know that age-related neurodegenerative diseases affect aging individuals
Why does basic research continue to make use of the immature nervous system or mutants that succumb early and die young? And could this explain why strategies that rescue immature neurons fail to translate into effective clinical treatments for neurodegenerative diseases in aging humans? Here I try to make sense of this current state of affairs and suggest a pragmatic way forward
Over the past 20–30 years we have witnessed much excitement following laboratory discoveries with the potential to translate into therapies for age-related neurodegenerative diseases (Oppenheim, 1996; Weissmiller and Wu, 2012), only to learn that these have failed in clinical trials (Glaser, 1997; Evans and Barker, 2008; Burns and Verfaillie, 2015), raising the question “what are we missing?” I suggest we are forgetting that age-related neurodegenerative diseases are just that: age-related
Summary
We all know that age-related neurodegenerative diseases affect aging individuals. Could this explain why strategies that rescue immature neurons fail to translate into effective clinical treatments for neurodegenerative diseases in aging humans?
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
